Nanoscope Therapeutics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Nanoscope Therapeutics sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Nanoscope Therapeutics: 6 sponsored US clinical trials, 1 recruiting.
Nanoscope Therapeutics sponsors 6 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 3 completed. 0 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Retinitis Pigmentosa, with 3 trials.
Upper-quartile sponsor footprint
Nanoscope Therapeutics sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
6 total, page 1 of 1
A Prospective Observational Study to Assess the Reliability and Validity of the MLSDT
NCT06805474
Non-Interventional Long Term Follow-up Study of Participants Previously Enrolled in the RESTORE Study
NCT06162585
Non-interventional Long Term Follow-up Study of Participants Previously Enrolled in the STARLIGHT Study
NCT06048185
Observational Study to Assess the Reliability and Validity of the MLYMT and MLSDT
NCT05820100
Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects With Stargardt Disease
NCT05417126
Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]
NCT04945772
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
Therapeutic Areas
What is open in the Nanoscope Therapeutics pipeline
1 recruiting of 6 indexed (17% open); 3 completed (50%).
Phase mix: 0 late (III/IV) vs 2 early (I/II) (early-phase heavy).
Top condition: Retinitis Pigmentosa (3 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Nanoscope Therapeutics: open-pipeline peers nationwide
Peers matched on 6 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Nanoscope Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 trials (± recruiting share)
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors near 17% open enrollment (± trial volume)
- Adagene · 17% recruiting · 6 trials
- Agendia · 17% recruiting · 6 trials
- Akamis Bio · 17% recruiting · 6 trials
- Angiodynamics · 17% recruiting · 12 trials
Related
What to do with this Nanoscope Therapeutics page
6 registered trials is a research-attention snapshot, not an endorsement of Nanoscope Therapeutics or any single study.
- 1 of Nanoscope Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Retinitis Pigmentosa is the condition Nanoscope Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Retinitis Pigmentosa trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Nanoscope Therapeutics pipeline card: 6 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.